CA
NZ
UK
AU
IND
US
DataMeds AI (NASDAQ:MEDS) closed down 11.14% at $3.11 as the company disclosed a settlement and release involving disputes tied to a Membership Interest Purchase Agreement. The move matters because the stock remains sharply below its 52-week high, while thin tradingVolumeand deep operating losses raise …
Braveheart Bio (NASDAQ:BRVE) closed down 11.77% at $20.62, extending a decline that has cut sharply from the stock this year. The move contrasts with analyst assessments ranging from Moderate Buy to Strong Buy, while thin tradingVolumeand elevated short interest add uncertainty around the selloff's …
ACADIA Pharmaceuticals (NASDAQ:ACAD) closed down 6.76% at $20.68 even as its remlifanserin program produced Phase Two topline results in Alzheimer's disease psychosis, with the 60 mg dose showing greater improvement than placebo on the primary measure at week 6. The data matter because ACADIA …
Xtant Medical (NYSE American:XTNT) and HeartBeam (NASDAQ:BEAT) are both small medical technology companies, but they sit at opposite points in the life cycle of a device business. Xtant generates about $100 million a year selling bone-graft and other biologic products to surgeons, and is …
STAAR Surgical (NASDAQ:STAA) authorized a $50 million share repurchase, with shares closing up 7.49% at $20.51. The announcement represents a corporate capital-allocation decision, while the share-price increase reflects how the market valued the news. A repurchase authorization gives the company permission to use the …
Vivos Therapeutics (NASDAQ:VVOS) and NexGel (NASDAQ:NXGL) sit at the small end of the Nasdaq-listed healthcare universe, and both spent 2025 and 2026 trying to grow through acquisitions rather than relying solely on organic sales. Vivos bought a chain of sleep clinics; NexGel bought a …
"Testing" covers very different businesses in healthcare. VivoSim Labs (NASDAQ:VIVS) sells lab services that check experimental drugs for toxicity before they reach people. VolitionRx (NYSE American:VNRX) develops blood tests that aim to detect disease in patients and pets. Both are microcaps with small revenue, …
Xtant Medical (NYSE American:XTNT) and HeartBeam (NASDAQ:BEAT) are both small medical technology companies, but they sit at opposite points in the life cycle of a device business. Xtant generates about $100 million a year selling bone-graft and other biologic products to surgeons, and is …
Cell therapy has produced some of oncology's most striking clinical results, yet developing these treatments is punishing for small companies. Senti Biosciences (NASDAQ:SNTI) and TScan Therapeutics (NASDAQ:TCRX), both Nasdaq-listed, show that tension clearly: each reported encouraging clinical signals in 2026, and each has since …
NeuropsychiatricDrug Developmentis notoriously difficult. Conditions such as social anxiety and agitation in dementia are measured with rating scales and patient-reported outcomes, placebo responses can be large, and a promising Phase 2 result does not always hold up in larger trials. Vistagen Therapeutics (NASDAQ:VTGN) and …
Please wait processing your request...